VYNE Therapeutics Inc.
VYNE
$0.36
-$0.01-2.11%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 144.93% | -65.84% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 144.93% | -65.84% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | 144.93% | -65.84% | |||
| SG&A Expenses | -0.92% | -16.64% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 4.60% | -19.02% | |||
| Operating Income | -3.31% | 17.99% | |||
| Income Before Tax | -29.22% | 33.20% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -29.22% | 33.20% | |||
| Earnings from Discontinued Operations | 1,925.00% | 0.00% | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -26.50% | 33.17% | |||
| EBIT | -3.31% | 17.99% | |||
| EBITDA | -3.32% | 18.01% | |||
| EPS Basic | -26.37% | 33.30% | |||
| Normalized Basic EPS | -5.24% | 18.25% | |||
| EPS Diluted | -26.37% | 33.30% | |||
| Normalized Diluted EPS | -5.24% | 18.25% | |||
| Average Basic Shares Outstanding | 0.10% | 0.20% | |||
| Average Diluted Shares Outstanding | 0.10% | 0.20% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||